- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT study: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes
Martine Piccart
Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
- Free
- slides video
- audio + slides
- All slides included
Discussant
Harold J Burstein
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial
Monica Arnedos
Institut Gustave Roussy, Villejuif, France
- Free
- slides video
- audio + slides
- All slides included
Discussant
Nancy E. Davidson
University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
Angela M DeMichele
University of Pennsylvania, Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Mark D Pegram
UCLA School of Medicine, Los Angeles, CA, United States
- Permission not
granted for presentation
Low-fat dietary pattern and breast cancer mortality in the Women's Health Initiative (WHI) randomized trial
Rowan T Chlebowski
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, United States
- Free
- slides video
- audio + slides
- All slides included
The tumor immunity continuum as a framework for rational combinations
Priti S Hegde
Genentech, South San Francisco, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Combinations using checkpoint blockade as one means to address resistance
Jedd D. Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
In vivo discovery of novel targets for cancer immunotherapy
Kai Wucherpfennig
Dana-Farber Cancer Inst., Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Invited speaker
Judy E. Garber
Dana-Farber Cancer Institute, Boston, MA, United States
- Permission not
granted for presentation
Invited speaker
Helen M. Piwnica-Worms
UT MD Anderson Cancer Center, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Invited speaker
Elizabeth M. Jaffee
Johns Hopkins University, Baltimore, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Invited speaker
Channing J. Der
UNC Lineberger Comp. Cancer Center, Chapel Hill, NC, United States
- Free
- audio + slides
- Some slides withheld
Invited speaker
David Malkin
Univ. of Toronto Hospital for Sick Children, Toronto, ON, Canada
- Free
- audio + slides
- Some slides withheld
Invited speaker
James P. Allison
UT MD Anderson Cancer Center, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
Invited Speaker
John M. Carethers
University of Michigan, Ann Arbor, MI, United States
- Permission not
granted for presentation
Invited Speaker
John D. Carpten
USC Keck School of Medicine, Los Angeles, CA, United States
- Free
- audio + slides
- Some slides withheld
Invited speaker
Pratip Bhattacharya
MD Anderson Center, Houston, TX, United States
- Permission not
granted for presentation
Invited speaker
William G. Kaelin
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- audio + slides
- Some slides withheld
Invited speaker
David J. Adams
Wellcome Trust Sanger Inst., Cambridge, United Kingdom
- Permission not
granted for presentation
Isogenic tumors can utilize heterogeneous mechanisms of nutrient uptake
Craig B. Thompson
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Permission not
granted for presentation
Transcriptional regulation by the MAX-like protein MLX is required for adaptive metabolic responses in development and tumorigenesis
Robert N. Eisenman
Fred Hutchinson Cancer Research Center, Seattle, WA, United States
- Permission not
granted for presentation
Targeted inhibition of IDHm in cancer
Katharine Yen
Agios Pharmaceuticals, Inc., Cambridge, MA, United States
- Permission not
granted for presentation
Nutrient sensing pathways in cancer
David M. Sabatini
MIT Whitehead Institute for Biomed. Research, Cambridge, MA, United States